Protocol Ledger

NCT04058158 · Phase III · COMPLETED

A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria

Interventional Phase III clinical trial protocol NCT04058158 sponsored by Samsung Bioepis Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-07 Enrollment: 50 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04058158
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)50 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04058158
Protocol FieldVerified Registry Value
NCT IdentifierNCT04058158
Consolidated Lead SponsorSamsung Bioepis Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment50 participants (ACTUAL)
Registered Start Date2019-08-07
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI